3 no-brainer dividend stocks to buy right now

AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market.

New study examines real-world switching patterns after patients transition from Humira to biosimilars

Analysis of nearly 68,000 patients finds biosimilar adoption increased following formulary changes; however, more than 1 in 7 patients switch back to HumiraBELLEVUE, Wash., June 29, 2026 (GLOBE ...

AbbVie broadens immunology focus with $10.9 billion Apogee deal

Seeking to replace blockbuster drugs that will soon lose patent protection, drug-maker AbbVie purchased a biotech firm for ...

The Number That Could Test AbbVie Stock

AbbVie's post-Humira growth story has been a triumph, but the single drug driving that narrative is showing the first hint of ...

AbbVie Sharpens Immunology Focus With $10.9 Billion Apogee Deal

AbbVie said on Monday it ⁠would ⁠buy Apogee Therapeutics for $10.9 billion, the ⁠company's largest buyout in more than five ...